Therapeutic effect of Peg-IFN therapy combined with RBV and simeprevir (SMV) on patients with chronic hepatitis C - a multicenter study -

Trial Profile

Therapeutic effect of Peg-IFN therapy combined with RBV and simeprevir (SMV) on patients with chronic hepatitis C - a multicenter study -

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 May 2016

At a glance

  • Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top